Literature DB >> 8740119

Physician preferences in the diagnosis and treatment of Lyme disease in the United States.

M H Ziska1, S T Donta, F C Demarest.   

Abstract

To assess physician preferences in the diagnosis and treatment of Lyme disease, questionnaires were sent to physicians in various Lyme disease endemic areas in the U.S. Seventy-eight responses were analyzed. Both ELISA and Western blot were ordered by 86% of responders. Fifty percent of responders believed that 25% or more of patients who have Lyme disease were seronegative. The treatment was influenced by physician specialty. Antibiotic treatment for tick bite was prescribed by 20% of responders. Erythema migrans rash was treated by all responders without serologic confirmation. The median treatment duration of erythema migrans was 4 weeks. For post-erythema migrans Lyme disease, 43% of responders treat 3 months or more; for chronic Lyme disease, 57% of responders treat 3 months or more. Our survey documents significant differences between published recommendations and actual practices. Physician education and clinical trials are needed to clarify the reasons for these differences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740119     DOI: 10.1007/bf01713336

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

1.  Serologic tests for Lyme disease. Interlaboratory variability.

Authors:  S W Luger; E Krauss
Journal:  Arch Intern Med       Date:  1990-04

2.  Clinical pathologic correlations of Lyme disease.

Authors:  P H Duray
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct

Review 3.  Disarming Lyme disease.

Authors:  F S Kantor
Journal:  Sci Am       Date:  1994-09       Impact factor: 2.142

Review 4.  Treatment of Lyme borreliosis.

Authors:  B J Luft; R J Dattwyler
Journal:  Rheum Dis Clin North Am       Date:  1989-11       Impact factor: 2.670

5.  Physician beliefs, attitudes, and approaches toward Lyme disease in an endemic area.

Authors:  S C Eppes; J D Klein; G M Caputo; C D Rose
Journal:  Clin Pediatr (Phila)       Date:  1994-03       Impact factor: 1.168

6.  Summary of the first 100 patients seen at a Lyme disease referral center.

Authors:  L H Sigal
Journal:  Am J Med       Date:  1990-06       Impact factor: 4.965

7.  A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites.

Authors:  E D Shapiro; M A Gerber; N B Holabird; A T Berg; H M Feder; G L Bell; P N Rys; D H Persing
Journal:  N Engl J Med       Date:  1992-12-17       Impact factor: 91.245

8.  Seronegative chronic relapsing neuroborreliosis.

Authors:  C Lawrence; R B Lipton; F D Lowy; P K Coyle
Journal:  Eur Neurol       Date:  1995       Impact factor: 1.710

Review 9.  Cutaneous manifestations of Lyme borreliosis.

Authors:  B W Berger
Journal:  Rheum Dis Clin North Am       Date:  1989-11       Impact factor: 2.670

Review 10.  Lyme disease: an infectious and postinfectious syndrome.

Authors:  E S Asch; D I Bujak; M Weiss; M G Peterson; A Weinstein
Journal:  J Rheumatol       Date:  1994-03       Impact factor: 4.666

View more
  4 in total

1.  Lyme disease: knowledge, beliefs, and practices of physicians in a low-endemic area.

Authors:  Bonnie Henry; Alexis Crabtree; David Roth; Doug Blackman; Muhammad Morshed
Journal:  Can Fam Physician       Date:  2012-05       Impact factor: 3.275

2.  Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.

Authors:  S V Onrust; K L Goa
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 3.  Systematic review of the treatment of early Lyme disease.

Authors:  P S Loewen; C A Marra; F Marra
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

4.  Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study.

Authors:  J Oksi; J Nikoskelainen; H Hiekkanen; A Lauhio; M Peltomaa; A Pitkäranta; D Nyman; H Granlund; S-A Carlsson; I Seppälä; V Valtonen; M Viljanen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.